Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anteris Technologies Global Corp. (AVR) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, giving investors a detailed view of its structural heart business and capital markets activity. As a medical instruments and supplies company focused on the DurAVR Transcatheter Heart Valve (THV) System, Anteris uses its filings to describe its technology, clinical programs and financial profile.
Through registration statements such as the Form S‑1, readers can review the company’s business overview, including its description of DurAVR THV as a balloon‑expandable biomimetic aortic valve, the role of its proprietary ADAPT tissue technology and the design of the ComASUR balloon‑expandable delivery system. These filings also outline the PARADIGM Trial, a global prospective randomized controlled trial comparing DurAVR THV to commercially available TAVR devices, and explain how the trial is intended to support a future Premarket Approval application and CE Mark progress.
Current reports on Form 8‑K document material events such as FDA IDE approval for PARADIGM, first patient enrollment and treatment in the pivotal trial, clinical data presentations, capital raising transactions involving common stock, CHESS Depositary Interests and warrants, and other corporate developments. Definitive proxy statements on Schedule 14A provide detail on the annual meeting agenda, director elections, equity incentive awards and stockholder voting procedures.
On Stock Titan, these filings are updated in near real time from EDGAR and can be paired with AI‑generated summaries that highlight key points from lengthy documents. Users can quickly locate quarterly reports on Form 10‑Q, annual reports on Form 10‑K (when filed), 8‑K event disclosures and registration statements, and use AI‑assisted explanations to understand complex sections such as risk factors, clinical trial descriptions, capital structure and equity compensation proposals.
For those analyzing AVR, the filings page offers a structured way to follow how Anteris presents its structural heart strategy, clinical evidence plans and financing arrangements to regulators and investors.
Anteris Technologies Global Corp. received an updated ownership filing showing that Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reported beneficial ownership of 3,143,154 shares of common stock as of December 31, 2025, representing 7.52% of the outstanding class.
This total includes 612,244 shares that may be acquired within sixty days through warrant exercises. The reporting persons have no sole voting or dispositive power but share voting and dispositive power over all reported shares, which are held in the ordinary course of business and not for the purpose of changing or influencing control.
L1 Capital Pty Ltd, as reporting person, disclosed large indirect purchases of Anteris Technologies Global Corp. common equity through funds it controls and manages. On 01/22/2026, investment funds managed by L1 Capital bought 5,000,000 shares of common stock at $5.75 per share, bringing their indirectly beneficially owned common shares to 13,219,814.
The filing also shows that on 10/28/2025, these funds purchased 1,333,334 CHESS Depository Interests at $4.935 each. Each CHESS Depository Interest represents one underlying share of Anteris common stock and is exchangeable for those shares within 60 days, giving exposure to the same number of underlying common shares.
L1 Capital Pty Ltd has filed an amended Schedule 13G reporting beneficial ownership of 13,219,814 shares of Anteris Technologies Global Corp. common stock, representing 13.6% of the outstanding shares. L1 Capital reports sole voting and dispositive power over these shares.
The position is held through multiple L1-branded funds that L1 Capital controls and manages. The filing amends a prior report that covered 8,219,814 shares and certifies that the securities are held without the purpose or effect of changing or influencing control of Anteris.
Medtronic plc, through its affiliate Covidien Group S.a.r.l., has acquired 15,652,173 shares of Anteris Technologies Global Corp. common stock, representing about 16.2% of the company. The shares were purchased in a private placement at $5.75 per share, for approximately $90 million funded from Covidien’s cash.
As part of the deal, Anteris granted Covidien registration rights for the resale of these shares and entered into an Investor Rights Agreement. Covidien receives a right to participate in certain future issuances, may appoint a non-voting board observer, and is subject to transfer restrictions and a customary standstill through May 22, 2027. The agreement also gives Covidien notice and negotiation rights if Anteris receives certain acquisition proposals.
Medtronic plc, as a 10% owner of Anteris Technologies Global Corp. (AVR), has filed an initial ownership report. The filing shows indirect beneficial ownership of 15,652,173 shares of common stock, which are held through Covidien Group S.a.r.l. rather than directly by Medtronic.
Anteris Technologies Global Corp. has a resale registration covering up to 9,103,796 shares of common stock that may be sold by existing stockholders under a prior Form S-1. This prospectus supplement adds information from recent current reports, including a new capital raise. The company entered into an underwritten public offering of 34,782,609 shares, plus an additional 5,217,391 shares sold under the underwriters’ option, at $5.75 per share, and a concurrent private placement of 15,652,173 shares at the same price to a Medtronic subsidiary. Combined gross proceeds from the offering and private placement are expected to be approximately $320 million, before fees and expenses. Anteris plans to use the cash to fund its DurAVR THV pivotal trial, expand manufacturing, support v2vmedtech research and development, and for working capital and general corporate purposes.
Anteris Technologies Global Corp. has a resale registration covering up to 9,103,796 shares of common stock that may be sold by existing stockholders under a prior Form S-1. This prospectus supplement adds information from recent current reports, including a new capital raise. The company entered into an underwritten public offering of 34,782,609 shares, plus an additional 5,217,391 shares sold under the underwriters’ option, at $5.75 per share, and a concurrent private placement of 15,652,173 shares at the same price to a Medtronic subsidiary. Combined gross proceeds from the offering and private placement are expected to be approximately $320 million, before fees and expenses. Anteris plans to use the cash to fund its DurAVR THV pivotal trial, expand manufacturing, support v2vmedtech research and development, and for working capital and general corporate purposes.
Anteris Technologies Global Corp. reported that Medtronic plc, through a wholly owned subsidiary, is making a strategic equity investment in the company. The investment is structured under a stock purchase agreement dated January 20, 2026 between Anteris and the Medtronic subsidiary.
On January 22, 2026, Anteris and Medtronic issued a joint press release about this transaction, which is furnished as Exhibit 99.1. The disclosure is provided under Regulation FD, meaning it is intended to share the same information with all market participants at the same time.
Anteris Technologies Global Corp. reported that Medtronic plc, through a wholly owned subsidiary, is making a strategic equity investment in the company. The investment is structured under a stock purchase agreement dated January 20, 2026 between Anteris and the Medtronic subsidiary.
On January 22, 2026, Anteris and Medtronic issued a joint press release about this transaction, which is furnished as Exhibit 99.1. The disclosure is provided under Regulation FD, meaning it is intended to share the same information with all market participants at the same time.
Anteris Technologies Global Corp. entered into an underwritten public offering and a concurrent private placement of its common stock. The company agreed to sell 34,782,609 shares in the offering at $5.75 per share, and granted underwriters a 30-day option for 5,217,391 additional shares, which was exercised in full. It also agreed to sell 15,652,173 shares at $5.75 per share in a private placement to Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc.
The combined transactions are expected to generate approximately $320 million in gross proceeds before fees and expenses. Anteris plans to use the net proceeds, together with existing cash, to support its next stage of growth, including the global pivotal PARADIGM Trial for its DurAVR® Transcatheter Heart Valve, expansion of manufacturing capabilities, funding ongoing research and development for v2vmedtech, inc., and for working capital and other general corporate purposes.
Anteris Technologies Global Corp. entered into an underwritten public offering and a concurrent private placement of its common stock. The company agreed to sell 34,782,609 shares in the offering at $5.75 per share, and granted underwriters a 30-day option for 5,217,391 additional shares, which was exercised in full. It also agreed to sell 15,652,173 shares at $5.75 per share in a private placement to Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc.
The combined transactions are expected to generate approximately $320 million in gross proceeds before fees and expenses. Anteris plans to use the net proceeds, together with existing cash, to support its next stage of growth, including the global pivotal PARADIGM Trial for its DurAVR® Transcatheter Heart Valve, expansion of manufacturing capabilities, funding ongoing research and development for v2vmedtech, inc., and for working capital and other general corporate purposes.
Anteris Technologies Global Corp. is issuing 34,782,609 shares of common stock at $5.75 per share in a primary public offering on Nasdaq. The deal is expected to raise approximately $189.8 million in gross proceeds before expenses, with net proceeds estimated at about $187.4 million, or $215.6 million if underwriters fully exercise a 5,217,391‑share option. Concurrently, a Medtronic plc subsidiary has agreed to buy 15,652,173 additional shares in a private placement at the same price, with expected net proceeds of about $84.4 million that are not registered in this prospectus.
After the offering and private placement, Anteris expects to have 86,497,152 shares outstanding, including CDIs. Proceeds, together with existing cash, will fund the PARADIGM pivotal trial of the DurAVR THV system for severe aortic stenosis, expand manufacturing capacity, and support R&D, including for v2vmedtech, plus working capital. The company is a development‑stage structural heart business with preliminary cash of about $12.6 million as of December 31, 2025 and an auditor going‑concern explanatory paragraph, and it acknowledges that investors in this offering will experience immediate dilution of $2.50 per share.
BlackRock, Inc. has updated its ownership disclosure for Anteris Technologies Global Corp common stock. BlackRock reports beneficial ownership of 2,026,967 shares, representing 4.9% of the outstanding common stock. It reports sole voting power over 1,997,796 shares and sole dispositive power over the full 2,026,967 shares, with no shared voting or dispositive power.
The filing explains that these holdings are attributed to certain BlackRock business units, and do not include any securities held by other disaggregated units. Various underlying persons have the right to receive dividends or sale proceeds from these shares, but no single person has more than five percent of the total outstanding common shares. BlackRock certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.